Q2 2026 13F · SEC CIK 1325083

Knoll Capital Management, LLC

Hedge fundFiled 2026-09-10 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $214.3M
Reported positions: 37
Top holdings a year, 3 yrs: +29.9%
Average holding period: 5.6 yrs

Knoll Capital Management, LLC is a hedge fund that reported 37 positions worth $214.3M in its Q2 2026 13F, filed 2026-09-10. Its largest holdings were Biohaven Pharmactl Hldg Co (16.3%), Meiragtx Hldgs PLC (MGTX, 7.9%), Sprott Asset Management LP (PHYS, 5.4%). A portfolio copying its top holdings returned 29.9% a year over the last 3 years, against 23.7% for the S&P 500.

Knoll Capital Management, LLC holdings all 37 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Knoll Capital Management, LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
G11196105Biohaven Pharmactl Hldg Co	16.3%	10.9%	2,352,520	+1.0%	$35.0M
MGTXMeiragtx Hldgs PLC	7.9%	6.0%	1,250,000	+0.0%	$16.9M
PHYSSprott Asset Management LP	5.4%	7.6%	387,055	+0.0%	$11.7M
ALDXAldeyra Therapeutics Inc	5.4%	5.1%	5,475,516	+0.0%	$11.7M
OCULOcular Therapeutix Inc	5.3%	2.8%	1,150,400	+91.6%	$11.3M
RGLDRoyal Gold Inc	4.9%	7.5%	52,750	+0.0%	$10.5M
ENTXEntera Bio Ltd	4.9%	3.6%	5,881,879	+0.0%	$10.4M
NUVBNuvation Bio Inc	4.2%	3.6%	1,598,591	+6.7%	$9.1M
AEMAgnico Eagle Mines Ltd	3.8%	5.9%	52,750	+0.0%	$8.2M
SASeabridge Gold Inc	3.8%	5.0%	317,003	+0.0%	$8.2M
KGCKinross Gold Corp	3.5%	5.4%	320,000	+0.0%	$7.6M
OROr Royalties Inc.	3.3%	0.0%	225,000	+0.0%	$7.1M
SSRMSsr Mng Inc	3.2%	4.0%	245,000	+0.0%	$6.9M
FNVFranco Nev Corp	3.1%	4.4%	32,000	+0.0%	$6.7M
BAHBooz Allen Hamilton Hldg Cor	2.7%	0.6%	13,000	+0.0%	$5.7M
CGAUCenterra Gold Incorporated (canada)	2.7%	3.5%	359,000	+0.0%	$5.7M
ELTXElicio Therapeutics Inc	2.2%	3.7%	1,211,957	+92.1%	$4.7M
ABVXAbivax SA	2.2%	New	35,000	—	$4.7M
PAASPan Amern Silver Corp	2.1%	3.0%	100,035	+0.0%	$4.5M
PSLVSprott Physical	2.0%	3.0%	222,160	+0.0%	$4.2M
TFPMTriple Flag Precious Metal	1.6%	2.2%	115,000	+0.0%	$3.4M
ABEOAbeona Therapeutics	1.4%	1.2%	485,515	+0.0%	$3.0M
GROYGold Royalty Corp	1.3%	2.0%	1,000,000	+0.0%	$2.8M
64782A107New Pac Metals Corp	0.9%	1.1%	485,000	+0.0%	$1.9M
ITAIshares Tr	0.9%	0.9%	7,650	+0.0%	$1.9M
PMPhilip Morris Intl Inc	0.8%	0.9%	10,000	+0.0%	$1.8M
CDECoeur Mng Inc	0.7%	1.0%	96,132	+0.0%	$1.6M
AGIAlamos Gold Inc	0.7%	1.2%	50,000	+0.0%	$1.5M
WPMWheaton Precious Metals Corp	0.7%	0.9%	12,500	+0.0%	$1.4M
NOCNorthrop Grumman Corp	0.5%	0.8%	2,165	+0.0%	$1.1M
ELEElemental Rty Corporation Com New (canad	0.4%	0.5%	50,000	+0.0%	$873K
VMETVersamet Royalties Corp	0.4%	0.4%	66,621	+0.0%	$821K
DCDakota Gold Corp	0.2%	0.3%	122,921	+0.0%	$524K
AMRZAmrize Ltd Shs	0.2%	0.3%	9,175	+0.0%	$489K
ALTAltimmune Inc	0.2%	0.3%	160,000	+0.0%	$486K
PHARPharming Group NV	0.0%	0.0%	4,091	+0.8%	$57K
68619K105Orgenesis, Inc.	0.0%	0.0%	50,623	+0.0%	$21K

What Knoll Capital Management, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

ABVX Abivax SA2.2% of 13F

Added to

ELTX Elicio Therapeutics Inc+92.1% shares
OCUL Ocular Therapeutix Inc+91.6% shares
NUVB Nuvation Bio Inc+6.7% shares

Reduced

No position shrank by more than 5%.

Sold out

CRDL Cardiol Therapeutics Incwas 0.1%

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +10.6% /yr; S&P 500 +20.1%
3 years: +29.9% /yr; S&P 500 +23.7%
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$214.3M	37
Q1 2026	$180.2M	37
Q4 2025	$218.0M	33
Q3 2025	$186.6M	38
Q2 2025	$140.7M	38
Q1 2025	$153.7M	36
Q4 2024	$155.3M	35
Q3 2024	$215.8M	36
Q2 2024	$148.4M	35
Q1 2024	$160.7M	34
Q4 2023	$120.8M	32
Q3 2023	$96.3M	37

Questions about Knoll Capital Management, LLC's portfolio

What stocks does Knoll Capital Management, LLC own?

Knoll Capital Management, LLC's latest 13F, for Q2 2026 and filed Sep 10, 2026, lists 37 positions worth $214.3M. The largest are Biohaven Pharmactl Hldg Co at 16.3%, Meiragtx Hldgs PLC (MGTX) at 7.9%, Sprott Asset Management LP (PHYS) at 5.4%, Aldeyra Therapeutics Inc (ALDX) at 5.4% and Ocular Therapeutix Inc (OCUL) at 5.3%.

What did Knoll Capital Management, LLC buy last quarter?

In Q2 2026, Knoll Capital Management, LLC added a new position in Abivax SA (ABVX), Elicio Therapeutics Inc (ELTX) (+92.1% shares), Ocular Therapeutix Inc (OCUL) (+91.6% shares) and Nuvation Bio Inc (NUVB) (+6.7% shares), compared with its Q1 2026 filing.

What did Knoll Capital Management, LLC sell last quarter?

In Q2 2026, Knoll Capital Management, LLC sold all of Cardiol Therapeutics Inc (CRDL), compared with its Q1 2026 filing.

How has Knoll Capital Management, LLC's portfolio performed?

A portfolio copying Knoll Capital Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +29.9% a year over the last 3 years, against +23.7% for the S&P 500. Over 1 year: +10.6% against +20.1%.

When is Knoll Capital Management, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Knoll Capital Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.